nodes	percent_of_prediction	percent_of_DWPC	metapath
Potassium Canrenoate—Areflexia—Cisplatin—bone cancer	0.0923	0.0953	CcSEcCtD
Potassium Canrenoate—Venous thrombosis—Carboplatin—bone cancer	0.0789	0.0814	CcSEcCtD
Potassium Canrenoate—Fluid overload—Carboplatin—bone cancer	0.0685	0.0707	CcSEcCtD
Potassium Canrenoate—Gastrointestinal ulcer haemorrhage—Cisplatin—bone cancer	0.0651	0.0672	CcSEcCtD
Potassium Canrenoate—Extravasation—Carboplatin—bone cancer	0.0488	0.0504	CcSEcCtD
Potassium Canrenoate—Phlebitis—Carboplatin—bone cancer	0.0359	0.037	CcSEcCtD
Potassium Canrenoate—Paresthesia of limbs—Methotrexate—bone cancer	0.0358	0.0369	CcSEcCtD
Potassium Canrenoate—Gastrointestinal ulcer haemorrhage—Methotrexate—bone cancer	0.0358	0.0369	CcSEcCtD
Potassium Canrenoate—Slurred speech—Cisplatin—bone cancer	0.0279	0.0288	CcSEcCtD
Potassium Canrenoate—Venous thrombosis—Cisplatin—bone cancer	0.0231	0.0239	CcSEcCtD
Potassium Canrenoate—Fluid overload—Cisplatin—bone cancer	0.0201	0.0207	CcSEcCtD
Potassium Canrenoate—Infection—Carboplatin—bone cancer	0.0151	0.0156	CcSEcCtD
Potassium Canrenoate—Extravasation—Cisplatin—bone cancer	0.0143	0.0148	CcSEcCtD
Potassium Canrenoate—Ulcer—Cisplatin—bone cancer	0.0132	0.0136	CcSEcCtD
Potassium Canrenoate—Dysarthria—Cisplatin—bone cancer	0.0132	0.0136	CcSEcCtD
Potassium Canrenoate—Pain—Carboplatin—bone cancer	0.013	0.0134	CcSEcCtD
Potassium Canrenoate—Hyperkalaemia—Cisplatin—bone cancer	0.0123	0.0127	CcSEcCtD
Potassium Canrenoate—Body temperature increased—Carboplatin—bone cancer	0.012	0.0124	CcSEcCtD
Potassium Canrenoate—Venous thrombosis—Epirubicin—bone cancer	0.0119	0.0123	CcSEcCtD
Potassium Canrenoate—Venous thrombosis—Doxorubicin—bone cancer	0.011	0.0113	CcSEcCtD
Potassium Canrenoate—Phlebitis—Cisplatin—bone cancer	0.0105	0.0109	CcSEcCtD
Potassium Canrenoate—Ileus—Epirubicin—bone cancer	0.00906	0.00935	CcSEcCtD
Potassium Canrenoate—Ileus—Doxorubicin—bone cancer	0.00838	0.00865	CcSEcCtD
Potassium Canrenoate—Extravasation—Methotrexate—bone cancer	0.00786	0.00811	CcSEcCtD
Potassium Canrenoate—Abdominal discomfort—Cisplatin—bone cancer	0.00751	0.00775	CcSEcCtD
Potassium Canrenoate—Extravasation—Epirubicin—bone cancer	0.00735	0.00759	CcSEcCtD
Potassium Canrenoate—Dysarthria—Methotrexate—bone cancer	0.00725	0.00748	CcSEcCtD
Potassium Canrenoate—Ulcer—Methotrexate—bone cancer	0.00725	0.00748	CcSEcCtD
Potassium Canrenoate—Extravasation—Doxorubicin—bone cancer	0.0068	0.00702	CcSEcCtD
Potassium Canrenoate—Dysarthria—Epirubicin—bone cancer	0.00678	0.007	CcSEcCtD
Potassium Canrenoate—Ulcer—Epirubicin—bone cancer	0.00678	0.007	CcSEcCtD
Potassium Canrenoate—Atrioventricular block—Epirubicin—bone cancer	0.00661	0.00683	CcSEcCtD
Potassium Canrenoate—Hyperkalaemia—Epirubicin—bone cancer	0.0063	0.0065	CcSEcCtD
Potassium Canrenoate—Dysarthria—Doxorubicin—bone cancer	0.00627	0.00648	CcSEcCtD
Potassium Canrenoate—Ulcer—Doxorubicin—bone cancer	0.00627	0.00648	CcSEcCtD
Potassium Canrenoate—Atrioventricular block—Doxorubicin—bone cancer	0.00612	0.00632	CcSEcCtD
Potassium Canrenoate—Hyperkalaemia—Doxorubicin—bone cancer	0.00583	0.00602	CcSEcCtD
Potassium Canrenoate—Arrhythmia—Cisplatin—bone cancer	0.0056	0.00578	CcSEcCtD
Potassium Canrenoate—Phlebitis—Epirubicin—bone cancer	0.0054	0.00558	CcSEcCtD
Potassium Canrenoate—Flatulence—Cisplatin—bone cancer	0.00538	0.00555	CcSEcCtD
Potassium Canrenoate—Hydrocortamate—CYP3A4—bone cancer	0.00524	0.168	CrCbGaD
Potassium Canrenoate—Cortisone acetate—CYP3A4—bone cancer	0.00516	0.165	CrCbGaD
Potassium Canrenoate—Phlebitis—Doxorubicin—bone cancer	0.005	0.00516	CcSEcCtD
Potassium Canrenoate—Discomfort—Cisplatin—bone cancer	0.00459	0.00474	CcSEcCtD
Potassium Canrenoate—Cardiac arrest—Epirubicin—bone cancer	0.00443	0.00457	CcSEcCtD
Potassium Canrenoate—Infection—Cisplatin—bone cancer	0.00443	0.00457	CcSEcCtD
Potassium Canrenoate—Drospirenone—PTGS2—bone cancer	0.00425	0.136	CrCbGaD
Potassium Canrenoate—Hypotension—Cisplatin—bone cancer	0.00416	0.0043	CcSEcCtD
Potassium Canrenoate—Abdominal discomfort—Methotrexate—bone cancer	0.00412	0.00426	CcSEcCtD
Potassium Canrenoate—Cardiac arrest—Doxorubicin—bone cancer	0.0041	0.00423	CcSEcCtD
Potassium Canrenoate—Paraesthesia—Cisplatin—bone cancer	0.004	0.00413	CcSEcCtD
Potassium Canrenoate—Pain—Cisplatin—bone cancer	0.00381	0.00393	CcSEcCtD
Potassium Canrenoate—Feeling abnormal—Cisplatin—bone cancer	0.00367	0.00379	CcSEcCtD
Potassium Canrenoate—Body temperature increased—Cisplatin—bone cancer	0.00352	0.00364	CcSEcCtD
Potassium Canrenoate—Haemoglobin—Methotrexate—bone cancer	0.00346	0.00357	CcSEcCtD
Potassium Canrenoate—Haemorrhage—Methotrexate—bone cancer	0.00344	0.00355	CcSEcCtD
Potassium Canrenoate—Haemoglobin—Epirubicin—bone cancer	0.00324	0.00334	CcSEcCtD
Potassium Canrenoate—Haemorrhage—Epirubicin—bone cancer	0.00322	0.00332	CcSEcCtD
Potassium Canrenoate—Asthenia—Cisplatin—bone cancer	0.0032	0.0033	CcSEcCtD
Potassium Canrenoate—Diarrhoea—Cisplatin—bone cancer	0.00305	0.00315	CcSEcCtD
Potassium Canrenoate—Haemoglobin—Doxorubicin—bone cancer	0.003	0.00309	CcSEcCtD
Potassium Canrenoate—Haemorrhage—Doxorubicin—bone cancer	0.00298	0.00308	CcSEcCtD
Potassium Canrenoate—Prednisone—CYP3A4—bone cancer	0.00291	0.0934	CrCbGaD
Potassium Canrenoate—Medroxyprogesterone Acetate—CYP3A4—bone cancer	0.0029	0.0929	CrCbGaD
Potassium Canrenoate—Arrhythmia—Epirubicin—bone cancer	0.00288	0.00297	CcSEcCtD
Potassium Canrenoate—Vomiting—Cisplatin—bone cancer	0.00283	0.00292	CcSEcCtD
Potassium Canrenoate—Rash—Cisplatin—bone cancer	0.00281	0.0029	CcSEcCtD
Potassium Canrenoate—Dermatitis—Cisplatin—bone cancer	0.00281	0.0029	CcSEcCtD
Potassium Canrenoate—Flatulence—Epirubicin—bone cancer	0.00276	0.00285	CcSEcCtD
Potassium Canrenoate—Methyltestosterone—CYP3A4—bone cancer	0.00273	0.0875	CrCbGaD
Potassium Canrenoate—Prednisolone—CYP3A4—bone cancer	0.00269	0.0861	CrCbGaD
Potassium Canrenoate—Arrhythmia—Doxorubicin—bone cancer	0.00266	0.00275	CcSEcCtD
Potassium Canrenoate—Nausea—Cisplatin—bone cancer	0.00265	0.00273	CcSEcCtD
Potassium Canrenoate—Flatulence—Doxorubicin—bone cancer	0.00256	0.00264	CcSEcCtD
Potassium Canrenoate—Discomfort—Methotrexate—bone cancer	0.00252	0.0026	CcSEcCtD
Potassium Canrenoate—Confusional state—Methotrexate—bone cancer	0.00247	0.00255	CcSEcCtD
Potassium Canrenoate—Infection—Methotrexate—bone cancer	0.00243	0.00251	CcSEcCtD
Potassium Canrenoate—Discomfort—Epirubicin—bone cancer	0.00236	0.00243	CcSEcCtD
Potassium Canrenoate—Confusional state—Epirubicin—bone cancer	0.00231	0.00238	CcSEcCtD
Potassium Canrenoate—Hypotension—Methotrexate—bone cancer	0.00228	0.00236	CcSEcCtD
Potassium Canrenoate—Infection—Epirubicin—bone cancer	0.00227	0.00235	CcSEcCtD
Potassium Canrenoate—Paraesthesia—Methotrexate—bone cancer	0.0022	0.00227	CcSEcCtD
Potassium Canrenoate—Discomfort—Doxorubicin—bone cancer	0.00218	0.00225	CcSEcCtD
Potassium Canrenoate—Hypotension—Epirubicin—bone cancer	0.00214	0.00221	CcSEcCtD
Potassium Canrenoate—Confusional state—Doxorubicin—bone cancer	0.00213	0.0022	CcSEcCtD
Potassium Canrenoate—Infection—Doxorubicin—bone cancer	0.0021	0.00217	CcSEcCtD
Potassium Canrenoate—Pain—Methotrexate—bone cancer	0.00209	0.00216	CcSEcCtD
Potassium Canrenoate—Paraesthesia—Epirubicin—bone cancer	0.00205	0.00212	CcSEcCtD
Potassium Canrenoate—Hydrocortisone—CYP3A4—bone cancer	0.00205	0.0659	CrCbGaD
Potassium Canrenoate—Feeling abnormal—Methotrexate—bone cancer	0.00202	0.00208	CcSEcCtD
Potassium Canrenoate—Gastrointestinal pain—Methotrexate—bone cancer	0.002	0.00206	CcSEcCtD
Potassium Canrenoate—Hypotension—Doxorubicin—bone cancer	0.00198	0.00204	CcSEcCtD
Potassium Canrenoate—Pain—Epirubicin—bone cancer	0.00196	0.00202	CcSEcCtD
Potassium Canrenoate—Body temperature increased—Methotrexate—bone cancer	0.00193	0.002	CcSEcCtD
Potassium Canrenoate—Abdominal pain—Methotrexate—bone cancer	0.00193	0.002	CcSEcCtD
Potassium Canrenoate—Paraesthesia—Doxorubicin—bone cancer	0.0019	0.00196	CcSEcCtD
Potassium Canrenoate—Feeling abnormal—Epirubicin—bone cancer	0.00189	0.00195	CcSEcCtD
Potassium Canrenoate—Gastrointestinal pain—Epirubicin—bone cancer	0.00187	0.00193	CcSEcCtD
Potassium Canrenoate—Pain—Doxorubicin—bone cancer	0.00181	0.00187	CcSEcCtD
Potassium Canrenoate—Abdominal pain—Epirubicin—bone cancer	0.00181	0.00187	CcSEcCtD
Potassium Canrenoate—Body temperature increased—Epirubicin—bone cancer	0.00181	0.00187	CcSEcCtD
Potassium Canrenoate—Asthenia—Methotrexate—bone cancer	0.00175	0.00181	CcSEcCtD
Potassium Canrenoate—Feeling abnormal—Doxorubicin—bone cancer	0.00174	0.0018	CcSEcCtD
Potassium Canrenoate—Gastrointestinal pain—Doxorubicin—bone cancer	0.00173	0.00179	CcSEcCtD
Potassium Canrenoate—Progesterone—CYP3A4—bone cancer	0.00167	0.0537	CrCbGaD
Potassium Canrenoate—Abdominal pain—Doxorubicin—bone cancer	0.00167	0.00173	CcSEcCtD
Potassium Canrenoate—Body temperature increased—Doxorubicin—bone cancer	0.00167	0.00173	CcSEcCtD
Potassium Canrenoate—Diarrhoea—Methotrexate—bone cancer	0.00167	0.00173	CcSEcCtD
Potassium Canrenoate—Asthenia—Epirubicin—bone cancer	0.00164	0.00169	CcSEcCtD
Potassium Canrenoate—Testosterone—CYP3A4—bone cancer	0.00158	0.0507	CrCbGaD
Potassium Canrenoate—Diarrhoea—Epirubicin—bone cancer	0.00157	0.00162	CcSEcCtD
Potassium Canrenoate—Vomiting—Methotrexate—bone cancer	0.00155	0.0016	CcSEcCtD
Potassium Canrenoate—Rash—Methotrexate—bone cancer	0.00154	0.00159	CcSEcCtD
Potassium Canrenoate—Dermatitis—Methotrexate—bone cancer	0.00154	0.00159	CcSEcCtD
Potassium Canrenoate—Asthenia—Doxorubicin—bone cancer	0.00152	0.00157	CcSEcCtD
Potassium Canrenoate—Vomiting—Epirubicin—bone cancer	0.00146	0.0015	CcSEcCtD
Potassium Canrenoate—Nausea—Methotrexate—bone cancer	0.00145	0.0015	CcSEcCtD
Potassium Canrenoate—Diarrhoea—Doxorubicin—bone cancer	0.00145	0.0015	CcSEcCtD
Potassium Canrenoate—Rash—Epirubicin—bone cancer	0.00144	0.00149	CcSEcCtD
Potassium Canrenoate—Dermatitis—Epirubicin—bone cancer	0.00144	0.00149	CcSEcCtD
Potassium Canrenoate—Nausea—Epirubicin—bone cancer	0.00136	0.0014	CcSEcCtD
Potassium Canrenoate—Vomiting—Doxorubicin—bone cancer	0.00135	0.00139	CcSEcCtD
Potassium Canrenoate—Rash—Doxorubicin—bone cancer	0.00134	0.00138	CcSEcCtD
Potassium Canrenoate—Dermatitis—Doxorubicin—bone cancer	0.00133	0.00138	CcSEcCtD
Potassium Canrenoate—Nausea—Doxorubicin—bone cancer	0.00126	0.0013	CcSEcCtD
